Abstract
Objective:To evaluate the effect of preoperative neoadjuvant chemotherapy regimen of XELOX (capecitabine combined with oxaliplatin) on surgical condition and oncogene expression in advanced gastric cancer.Methods:From January 2015 to July 2016, 124 patients with advanced gastric cancer who were admitted to our hospital were selected. Random number table method was used to divide them into an observation group and a control group, 62 each group. The observation group received two courses of neoadjuvant chemotherapy (XELOX) before operation, and the control group received surgery. The operation condition, expression of oncogenes in gastric cancer lesions, occurrence of adverse reactions and the long-term prognosis were compared between the two groups.Results:The R0 resection rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). The operation time of the observation group was shorter than that of the control group, the amount of intraoperative bleeding and the amount of postoperative drainage of the observation group were less than that of the control group, and the differences were statistically significant (P<0.05). The mRNA expression of gastrokine 1, multiple tumor suppressor protein, Wilms tumor gene on the X chromosome (WTX gene) and gene of phosphate and tension homology deleted on chromosome ten (PTEN gene) in the observation group after treatment was significantly higher than that in the control group before treatment, and the increase amplitude of the observation group was more obvious than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). In terms of long-term prognosis, the disease-free survival time and average survival time of the observation group during the two-year follow-up period were significantly better than those of the control group, and the recurrence rate of the observation group was significantly lower than that of the control group; the differences were statistically significant (P<0.05).Conclusion:Preoperative XELOX for advanced gastric cancer patients can effectively increase the proportion of radical surgery, reduce the risk of surgery, and significantly regulate the expression of oncogene, thus improving the long-term prognosis of patients.
Highlights
INTRODUCTIONOne of the most common malignant tumors of digestive system. In recent years, due to the deterioration of the environment and the change of people’s lifestyle, the morbidity and mortality of gastric cancer remain high.[1,2] Early detection and
Gastric cancer, one of the most common malignant tumors of digestive system
The purpose of this study was to explore the effect of XELOX chemotherapy regimen in preoperative chemotherapy for advanced gastric cancer, in order to provide a theoretical basis for clinical practice
Summary
One of the most common malignant tumors of digestive system. In recent years, due to the deterioration of the environment and the change of people’s lifestyle, the morbidity and mortality of gastric cancer remain high.[1,2] Early detection and. Advanced gastric cancer has strong growth and infiltration activity, and local lesions will have adjacent tissue infiltration and lymph node metastasis. Neoadjuvant chemotherapy refers to systemic chemotherapy before local treatment such as surgery or radiotherapy, which aims at shrinking the mass and killing the invisible metastatic cells as early as possible to facilitate follow-up surgery and radiotherapy.[6,7] A study has shown that preoperative neoadjuvant chemotherapy can effectively remove occult and small lesions and reduce the stage of tumors,[8] which can improve prognosis and prolong survival. The purpose of this study was to explore the effect of XELOX (capacitating combined with oxaliplatin) chemotherapy regimen in preoperative chemotherapy for advanced gastric cancer, in order to provide a theoretical basis for clinical practice
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
